Take a look at some of the Europeans involved in EuroMED. These people have outstanding resumes.
Dr. Thomas Sebastian Vetter entered into a landmark partnership to produce cultured cannabinoids at scale. Using biosynthesis as the means of production, will reduce the cost of pure cannabinoid production, create commercial scale and the ability to access rare cannabinoids, which are key to product differentiation. EuroMED will have the exclusive right to use and commercialize the key patented intellectual property related to the production of the target cannabinoids perpetually and globally.
Dr. Med. PhD. Thomas Sebastian Vette Managing Director & Chief Scientist, Canalytics AG, Zurich. Dr. Vette is Chief Scientist of Speropharm GmbH, St. Gallen, and Managing Director and Chief Scientist, Canalytics AG, Zurich. Canalytics AG, main activities are in the field of cannabis research and development, specifically genetical research and development of new cannabis strains He is president of the board of directors, Stem Cell Bank of Switzerland, Zurich,. He also is clinic director and leading physician of Futuremed Clinic Zurich planning and development of a new holistic concept based on a private clinic setup, including clinical services of different medical disciplines with an integrated research facility, laboratory, surgical theatres and intermediate care infrastructure, all within a fully integrated teaching environment.
Tanner Sanner Director of Swiss Operations Tanner has been instrumental in providing the seed capital to start the two cultivation facilities in Staad and Herisau, assembled the cultivation team and marketing and sales of SpreoPharma’s products. He also communicates on behalf of the company with government entities and the public. He leads the development of the company’s short-and long term Cannabis strategy, creates and implementing the company’s vision and mission. He provides EuroMED with market awareness of the competitive market landscape, expansion opportunities, and industrial developments. He also ensures that the company maintains high social responsibility where it does business.
My impression is that this individual (Tanner Sanner) has deep pockets and has funded much of the expansion into Europe while EuroMED Israel is still trying to get their act together.
Kgem
Dr. Thomas Sebastian Vetter entered into a landmark partnership to produce cultured cannabinoids at scale. Using biosynthesis as the means of production, will reduce the cost of pure cannabinoid production, create commercial scale and the ability to access rare cannabinoids, which are key to product differentiation. EuroMED will have the exclusive right to use and commercialize the key patented intellectual property related to the production of the target cannabinoids perpetually and globally.
Dr. Med. PhD. Thomas Sebastian Vette Managing Director & Chief Scientist, Canalytics AG, Zurich. Dr. Vette is Chief Scientist of Speropharm GmbH, St. Gallen, and Managing Director and Chief Scientist, Canalytics AG, Zurich. Canalytics AG, main activities are in the field of cannabis research and development, specifically genetical research and development of new cannabis strains He is president of the board of directors, Stem Cell Bank of Switzerland, Zurich,. He also is clinic director and leading physician of Futuremed Clinic Zurich planning and development of a new holistic concept based on a private clinic setup, including clinical services of different medical disciplines with an integrated research facility, laboratory, surgical theatres and intermediate care infrastructure, all within a fully integrated teaching environment.
Tanner Sanner Director of Swiss Operations Tanner has been instrumental in providing the seed capital to start the two cultivation facilities in Staad and Herisau, assembled the cultivation team and marketing and sales of SpreoPharma’s products. He also communicates on behalf of the company with government entities and the public. He leads the development of the company’s short-and long term Cannabis strategy, creates and implementing the company’s vision and mission. He provides EuroMED with market awareness of the competitive market landscape, expansion opportunities, and industrial developments. He also ensures that the company maintains high social responsibility where it does business.
My impression is that this individual (Tanner Sanner) has deep pockets and has funded much of the expansion into Europe while EuroMED Israel is still trying to get their act together.
Kgem
3
